There are 360 resources available
190P - Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale
Presenter: CARINE PATUREL
Session: Poster Display
84P - Ambulatory management of ICI-induced hepatitis: a safe and effective management approach
Presenter: Anna Olsson-Brown
Session: Poster Display
192P - Safety and clinical activity of IOA-244, a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I First in Human (FIH) study.
Presenter: Anna Di Giacomo
Session: Poster Display
193P - CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform
Presenter: Alberto Toso
Session: Poster Display
87P - Infliximab use in patients with checkpoint inhibitor toxicities - a tertiary centre experience
Presenter: Shuai Zhang
Session: Poster Display
194P - Thermal ablation followed by intratumoral injection of a novel immune stimulant IP-001 in patients with advanced solid tumors: Phase IB part of study SAKK 66/17
Presenter: Markus Joerger
Session: Poster Display
88P - Hepatic arterial infusion chemotherapy(HAIC) + Lenvatinib(len) and tislelizumab(tis) ±transhepatic arterial embolization(TAE) for unresectable hepatocellular carcinoma(uHCC) with portal vein tumor thrombus(PVTT) and high tumor-burden: A multicenter retrospective study
Presenter: WENBO GUO
Session: Poster Display